LONDONâ€”GlaxoSmithKline PLC's decision to leave the hot field of cancer drugs narrows the focus of its business to just four areas: respiratory and HIV treatments, vaccines and consumer-health products.. The move, included in a series of transactions announced Tuesday that will reshape both Glaxo and Novartis AG, is part of a trend for pharmaceutical companies to focus on a handful of "core disease areas" to gain scale and unlock value. Recent decisions by Pfizer Inc., Novartis and Merck & Co. to divest or spin...
  